Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 20:19:992-1016.
doi: 10.17179/excli2020-2554. eCollection 2020.

Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020

Ahmed Nabil  1   2   3 , Koichiro Uto  1 , Mohamed M Elshemy  4 , Reham Soliman  3   5 , Ayman A Hassan  3 , Mitsuhiro Ebara  1   6   7 , Gamal Shiha  3   8
Affiliations
Review

Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020

Ahmed Nabil et al. EXCLI J. .

Abstract

Coronaviruses are a group of enveloped viruses with non-segmented, single-stranded, and positive-sense RNA genomes. In December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in Wuhan City, China. The World Health Organization (WHO) declared the coronavirus outbreak as a global pandemic in March 2020. Fever, dry cough and fatigue are found in the vast majority of all COVID-19 cases. Early diagnosis, treatment and future prevention are keys to COVID-19 management. Currently, the unmet need to develop cost-effective point-of-contact test kits and efficient laboratory techniques for confirmation of COVID-19 infection has powered a new frontier of diagnostic innovation. No proven effective therapies or vaccines for SARS-CoV-2 currently exist. The rapidly increasing research regarding COVID-19 virology provides a significant number of potential drug targets. Remdesivir may be the most promising therapy up till now. On May 1, 2020, Gilead Sciences, announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational Remdesivir as a potential antiviral for COVID-19 treatment. On May 7, 2020, Gilead Sciences, announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury® (Remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19 acute respiratory syndrome, under an exceptional approval pathway. Also, Corticosteroids are recommended for severe cases only to suppress the immune response and reduce symptoms, but not for mild and moderate patients where they are associated with a high-risk side effect. Based on the currently published evidence, we tried to highlight different diagnostic approaches, side effects and therapeutic agents that could help physicians in the frontlines.

Keywords: COVID-19; Diagnosis; Epidemiology; Remdesivir; SARS-CoV-2; Therapy.

PubMed Disclaimer

Figures

Table 1
Table 1. Current SARS-CoV-2 diagnostic tools and techniques
Table 2
Table 2. Different SARS-CoV-2 therapeutic approaches and mechanisms
Figure 1
Figure 1. Novel coronavirus COVID-19 geographical distribution over the word 2020-05-09 (ECDC, 2020)
Figure 2
Figure 2. Countries beating COVID-19 in alphabetical order (EndCoronavirus, 2020)
Figure 3
Figure 3. Countries that are nearly there (EndCoronavirus, 2020)
Figure 4
Figure 4. Countries that need to do an action (EndCoronavirus, 2020)
Figure 5
Figure 5. The Diagnostic Model for COVID-19
See this image and copyright information in PMC

References

    1. Afra TP, Vasudevan Nampoothiri R, Razmi TM. Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection. Eur J Haematol. 2020;epub ahead of print. - PMC - PubMed
    1. Aneja J, Goya D, Choudhary B. Psychosis consequent to antimalarial drug use in a young child. Family Med Prim Care. 2019;8:1781–1783. - PMC - PubMed
    1. Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020;55(4):105944. - PMC - PubMed
    1. Beauverd Y, Adam Y, Assouline B, Samii K. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. Eur J Haematol. 2020;epub ahead of print - PMC - PubMed
    1. Beutler E. G6PD deficiency. Blood. 1994;84:3613–3636. - PubMed

LinkOut - more resources